Edgewise Therapeutics, Inc.
EWTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$39.53
KIRA · Stoqly’s AI analyst, in plain words
- Edgewise Therapeutics, Inc. lost $168M in fiscal 2025.
- Free cash flow was −$144M in fiscal 2025, — of revenue.
Market cap
$4.3B
P/E
—
Revenue
—
Net income
−$168M
Free cash flow
−$144M
Operating margin
—
Edgewise Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$168M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Edgewise Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Edgewise Therapeutics, Inc.
- CIK
- 0001710072
Edgewise Therapeutics, Inc. · EWTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$42.8M | −$67.6M | −$100M | −$134M | −$168M |
| Diluted EPS | −$1.14 | −$1.26 | −$1.57 | −$1.45 | −$1.63 |
| Cash | |||||
| Cash from operations | −$33.5M | −$52.6M | −$91.9M | −$109M | −$144M |
| Capital expenditure | $0.7M | $5.5M | $5.7M | $1.3M | $0.3M |
| Free cash flow | −$34.2M | −$58.2M | −$97.7M | −$110M | −$144M |
| Share count change | 4,978.0% | 42.8% | 18.9% | 45.0% | 11.4% |
| Debt and strength | |||||
| Cash and short-term investments | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Shareholders' equity | $274M | $347M | $319M | $459M | $522M |
| Current ratio | 27.0x | 21.5x | 19.5x | 19.9x | 19.9x |
| Returns and quality | |||||
| Return on equity | −35.5% | −21.8% | −30.1% | −34.4% | −34.2% |
| Return on tangible equity | −15.6% | −19.5% | −31.4% | −29.1% | −32.1% |
| Altman Z'' | 30.9 | 21.3 | 17.2 | 18.8 | 18.6 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$19.5M
6 insiders
Of sales under plans
80%
$15.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Edgewise Therapeutics, Inc. · EWTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $39.53 a share, the company is worth $4.3B.
Source: SEC EDGAR XBRL filings (CIK 0001710072). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.